Overview
- Europe’s regulator is reported to be close to approving teplizumab to delay type 1 onset, after U.S. approval in 2023, with Italy funding child screening and the Basque Country piloting population tests to identify candidates early.
- Public campaigns in Spain are offering on‑the‑spot glucose and blood‑pressure checks and showcasing diabetes technology, alongside a push for more supportive workplaces for people living with the disease.
- The burden remains large and underdiagnosed: about 14% of Spanish adults have diabetes, Mexico reports roughly 1 in 10 adults with millions undiagnosed, and Argentina counts more than 4 million cases with an estimated 40% unaware.
- Clinicians stress that type 2 diabetes sharply raises cardiovascular risk and accounts for up to 40% of chronic kidney disease, reinforcing calls for routine lab checks and early detection.
- Care is shifting with highly effective GLP‑1/GIP drugs such as semaglutide and tirzepatide, while experts emphasize that lifestyle changes can reverse prediabetes and that wider access to CGM, pumps and automated insulin delivery is improving management.